Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at IR@chemomab.com.
About
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open
Contacts:
Media and Investors:
Consulting Vice President, Investor & Public Relations,
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
Source:
2024 GlobeNewswire, Inc., source